Voronoi

310210.KQ

83.91 USD

-4.63

-5.23%

Overview

Last close

83.91 usd

Market cap

1.54B usd

52 week high

242.93 usd

52 week low

65.70 usd

Target price

251.79 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

498.8313

Price/Book Value

39.1224

Enterprise Value

1.96B usd

EV/Revenue

624.2289

EV/EBITDA

-15.8405

Key financials

Revenue TTM

3.08M usd

Gross Profit TTM

3.08M usd

EBITDA TTM

-58.40M usd

Earnings per Share

-2.79 usd

Dividend

N/A usd

Total assets

86.41M usd

Net debt

4.01M usd

About

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.